. 2009 Jan 21;2009(1):CD003026.

doi: 10.1002/14651858.CD003026.pub3.

Treatment for amphetamine psychosis

Steven J Shoptaw¹, Uyen Kao, Walter Ling

Affiliations

Affiliation

¹ Department of Family Medicine, University of California, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90024, USA. sshoptaw@mednet.ucla.edu

PMID: 19160215
PMCID: PMC7004251
DOI: 10.1002/14651858.CD003026.pub3

Treatment for amphetamine psychosis

Steven J Shoptaw et al. Cochrane Database Syst Rev. 2009.

. 2009 Jan 21;2009(1):CD003026.

doi: 10.1002/14651858.CD003026.pub3.

Authors

Steven J Shoptaw¹, Uyen Kao, Walter Ling

Affiliation

¹ Department of Family Medicine, University of California, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90024, USA. sshoptaw@mednet.ucla.edu

PMID: 19160215
PMCID: PMC7004251
DOI: 10.1002/14651858.CD003026.pub3

Abstract

Background: Chronic amphetamine users may have experience of paranoia and hallucination. It has long been believed that dopamine antagonists, such as chlorpromazine, haloperidol, and thioridazine, are effective for the treatment of amphetamine psychosis.

Objectives: To evaluate risks, benefits, costs of treatments for amphetamine psychosis.

Search strategy: MEDLINE (1966-2007), EMBASE (1980-2007), CINAHL (1982-2007), PsychINFO (1806-2007), CENTRAL (Cochrane Library 2008 issue 1), references of obtained articles.

Selection criteria: All randomised controlled and clinical trials (RCTs, CCTs) evaluating treatments (alone or combined) for people with amphetamine psychosis

Data collection and analysis: Two authors evaluated and extracted the data independently. Dichotomous data were extracted on an intention-to-treat basis in which the dropouts were assigned as participants with the worst outcomes. The Relative Risk (RR) with the 95% confidence interval (95% CI) was used to assess the dichotomous data. The Weighted Mean Difference (WMD) with 95% CI was used to assess the continuous data.

Main results: The comprehensive searches found one randomised controlled trial of treatment for amphetamine psychosis meeting the criteria for considering studies. The study involved 58 participants and compared the efficacy and tolerability of two antipsychotic drugs, olanzapine (a newer antipsychotic) and haloperidol (a commonly used antipsychotic medication used as a control condition), in treating amphetamine-induced psychosis. The results show that both olanzapine and haloperidol at clinically relevant doses were efficacious in resolving psychotic symptoms, with the olanzapine condition showing significantly greater safety and tolerability than the haloperidol control as measured by frequency and severity of extrapyramidal symptoms.

Authors' conclusions: Only one RCT of treatment for amphetamine psychosis has been published. Outcomes from this trial indicate that antipsychotic medications effectively reduce symptoms of amphetamine psychosis, the newer generation and more expensive antipsychotic medication, olanzapine, demonstrates significantly better tolerability than the more affordable and commonly used medication, haloperidol.There are other two studies that did not meet the inclusion criteria for this review. The results of these two studies show that agitation and some psychotic symptoms may be abated within an hour after antipsychotic injection.Whether this limited evidence can be applied for amphetamine psychotic patients is not yet known.The medications that should be further investigate are conventional antipsychotics, newer antipsychotics and benzodiazepines. However, naturalistic studies of amphetamine psychotic symptoms and the prevalence of relapse to psychosis in the presence of amphetamine, are also crucial for advising the development of study designs appropriate for further treatment studies of amphetamine psychosis.

PubMed Disclaimer

Conflict of interest statement

None

Update of

Treatment for amphetamine psychosis.
Shoptaw SJ, Kao U, Ling WW. Shoptaw SJ, et al. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD003026. doi: 10.1002/14651858.CD003026.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003026. doi: 10.1002/14651858.CD003026.pub3. PMID: 18843639 Updated. Review.

References

References to studies included in this review

Leelahanaj 2005 {published data only}

1. Leelahanaj T, Kongsakon R, Netrakom P. A 4‐week, double‐blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. Journal of the Medical Association of Thailand 2005;88 Suppl 3:43‐52. - PubMed

References to studies excluded from this review

Baker 2006 {published data only}

1. Baker A, Bucci S, Lewin TJ, Kay‐Lambkin F, Constable PM, Carr VJ. Cognitive‐behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. British Journal of Psychiatry 2006;188:439‐48. - PubMed

Batki 2004 {published data only}

1. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. American Journal on Addictions 2004;13(5):461‐70. - PubMed

Breier 1999 {published data only}

1. Breier A, Su TP, Malhotra AK, Elman I, Adler CM, Weisenfeld NI, Pickar D. Effects of atypical antipsychotic drug treatment on amphetamine‐induced striatal dopamine release in patients with psychotic disorders. Neuropsychopharmacology 1999;20(4):340‐5. - PubMed

Brown 2003 {published data only}

1. Brown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ. Cocaine and amphetamine use in patients with psychiatric illness: a randomised trial of typical antipsychotic continuation or discontinuation. Journal of Clinical Psychopharmacology 2003;23(4):384‐8. - PubMed

Chen 2005 {published data only}

1. Chen CK, Lin SK, Pak CS, Ball D, Loh EW, Murray RM. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2005;136(1):87‐91. - PubMed

Richards 1997 {published data only}

1. Richards JR, Derlet RW, Duncan DR. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. European Journal of Emergency Medicine 1997;4:130‐5. - PubMed

Srisurapanont 2003 {published data only}

1. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in‐patients. International Journal of Neuropsychopharmacology 2003;6(4):347‐52. - PubMed

Additional references

Akiyama 2006

1. Akiyama, K. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long‐term abstinence. Annals of the New York Academy of Sciences 2006;1074:125‐34. - PubMed

Altman 1996

1. Altman J, Everitt BJ, Glautier S, Markou A, Nutt D, Oretti R, Phillips GD, Robbins TW. The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology 1996;125:285‐345. - PubMed

Angrist 1974

1. Angrist B, Lee HK, Gershon S. The antagonism of amphetamine‐induced symptomatology by a neuroleptic. American Journal of Psychiatry 1974;131:817‐9. - PubMed

Armstrong 2004

1. Armstrong BD, Noguchi KK. The neurotoxic effects of 3, 4‐methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA‐ergic terminals: an in‐vitro autoradiographic study in rats. Neurotoxicology 2004;25(6):905‐14. - PubMed

Beckett 1965

1. Beckett AH, Rowland M, Turner P. Influence of urinary pH on excretion of amphetamine. Lancet 1965;1:303. - PubMed

Chang 2006

1. Chang L, Haning W. Insights from recent positron emission tomographic studies of drug abuse and dependence. Current Opinion in Psychiatry 2006;19(3):246‐52. - PubMed

Dore 2006

1. Dore G, Sweeting M. Drug‐induced psychosis associated with crystalline methamphetamine. Australasian Psychiatry 2006;14(1):86‐9. - PubMed

Ellinwood 1977

1. Ellinwood Jr EH, Petrie WM. Dependence on amphetamine, cocaine, and other stimulants. In: Pradhan SN, Dutta SN editor(s). Drug abuse: clinical and basic concepts. St Louis: CV Mosby, 1977:248‐62.

Farrell 2002

1. Farrell M, Marsden J, Ali R, Ling W. Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction 2002;97(7):771‐2. - PubMed

Fowler 2007

1. Fowler JS, Kroll C, Ferrieri R, Alexoff D, Logan J, Dewey SL, Schiffer W, Schlyer D, Carter P, King P, Shea C, Xu Y, Muench L, Benveniste H, Vaska P, Volkow ND. PET studies of d‐methamphetamine pharmacokinetics in primates: comparison with l‐methamphetamine and (‐)‐cocaine. Journal of Nuclear Medicine 2007;48(10):1724‐32. - PMC - PubMed

Fujii 2002

1. Fujii D. Risk factors for treatment‐resistive methamphetamine psychosis. Journal of Neuropsychiatry and Clinical Neurosciences 2002;14(2):239‐40. - PubMed

Gray 2007

1. Gray SD, Fatovich DM, McCoubrie DL, Daly FF. Amphetamine‐related presentations to an inner‐city tertiary emergency department: A prospective evaluation. Medical Journal of Australia 2007;186:336‐339. - PubMed

Higgins 2006

1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd..

Hofmann 1983

1. Hofmann FG. A handbook on drug and alcohol abuse: the biomedical aspects. 2nd Edition. New York: Oxford University Press, 1983.

Jernigan 2005

1. Jernigan TL, Gamst AC, Archibald SL, Fennema‐Notestine C, Mindt MR, Marcotte TD, Heaton RK, Ellis RJ, Grant I. Effects of methamphetamine dependence and HIV infection on cerebral morphology. American Journal of Psychiatry 2005;162(8):1461‐72. - PubMed

Leland 2008

1. Leland DS, Arce E, Miller DA, Paulus MP. Anterior cingulate cortex and benefit of predictive cueing on response inhibition in stimulant dependent individuals. Biological Psychiatry 2008;63(2):184‐90. - PubMed

Leucht 1999

1. Leucht S, Pitschel‐Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomised controlled trials. Schizophrenia Research 1999;35(1):51‐68. - PubMed

Martin 2006

1. Martin I, Lampinen TM, McGhee D. Methamphetamine use among marginalized youth in British Columbia. Canadian Journal of Public Health 2006;97(4):320‐4. - PMC - PubMed

McIver 2006

1. McIver C, McGregor C, Baigent M, Spain D, Newcombe D, Ali R. Guidelines for the medical management of patients with methamphetamine‐induced psychosis. Drug and Alcohol Services: South Australia 2006.

McKetin 2006

1. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006;101(10):1473‐8. - PubMed

Meredith 2005

1. Meredith CW, Jaffe C, Ang‐Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harvard Review of Psychiatry 2005;13(3):141‐54. - PubMed

Paulus 2002

1. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine‐dependent subjects. Neuropsychopharmacology 2002;26(1):53‐63. - PubMed

Sato 1992

1. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia Bulletin 1992;18(1):115‐22. - PubMed

Schulz 1995

1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality assocaited with estimates of treatment effects in controlled trial. Journal of the American Medical Association 1995;273:408‐12. - PubMed

Sweeting 2005

1. Sweeting M, Farrell M. Methamphetamine psychosis: How is it related to schizophrenia, a review of the literature. Current Psychiatry Review 2005;1:115‐122.

Ujike 2004

1. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Annals of the New York Academy of Sciences 2004;1025:279‐87. - PubMed

Volkow 2001

1. Volkow ND, Chang L, Wang G, Fowler JS, Leonido‐Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding Y, Logan J, Wong C, Miller EN. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry 2001;158(3):377‐82. - PubMed

Yui 1997

1. Yui K, Ishiguro T, Goto K, Ikemoto S. Precipitating factors in spontaneous recurrence of methamphetamine psychosis. Psychopharmacology 1997;134(3):303‐8. - PubMed

Yui 2000

1. Yui K, Ishiguro T, Goto K, Ikemoto S. Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis. Annals of the New York Academy of Sciences 2000;914:292‐302. - PubMed

Yui 2002

1. Yui K, Ikemoto S, Goto K. Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. Annals of the New York Academy of Sciences 2002;965:292‐304. - PubMed

References to other published versions of this review

Srisurapanont 2001

1. Srisurapanont M, Kittiratanapaiboon P, Jarusuraisin N. Treatment from amphetamine psychosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003026] - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed